SCHEMBL4390778

SCHEMBL4390778

COCC(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
POLB P06746 2/20 0.39
CYP3A4 P08684 2/20 0.39
PDE2A O00408 3/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PREP P48147 1/20 0.38
FAP Q12884 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
LIPC P11150 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
AHR P35869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4383435 0.90 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL5668017 0.88 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL5670705 0.87 ALDH1A1 (0.40) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL4394123 0.86 ALDH1A1 (0.41) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL5668567 0.86 PDE2A (0.47) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL5667723 0.85 ABL1 (0.44) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL2172250 0.85 MEN1 (0.45) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL4389979 0.84 PDE2A (0.49) ALDH1A1PDE2AHPGDMAPT
SCHEMBL4383956 0.83 PDE2A (0.46) ALDH1A1PDE2ASMN1; SMN2KMT2AKDM4E
SCHEMBL4387739 0.83 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP2C9CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US claimed
EP-1730128-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-12-13 EP claimed
WO-2005097765-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-10-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 ALDH1A1 1466/4885CYP1A2 3488/4885CYP2C9 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.